Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Prediction of EGFR blockade responses in metastatic colorectal carcinoma].

Ceskoslovenska patologie - 1 Jan 2000

Fabian Pavel, Němeček Radim

Abstract excerpt

The combination of modern systemic chemotherapy and anti-EGFR monoclonal antibodies improves overall survival and the quality of life for patients with metastatic colorectal cancer. By contrast, the addition of anti-EGFR therapy to the treatment regime of resistant patients may lead to worse progression-free and overall survival. Therofore, identifying sensitive and resistant patients is key during initial...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to Class I Phosphatidylinositol 3-Kinases
Share to ErbB Receptors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Phosphatidylinositol 3-Kinases

Share to Proto-Oncogene Proteins B-raf

Share to Proto-Oncogene Proteins p21(ras)

Share to Quality of Life

Share to Receptor, ErbB-2

Source

Identifiers

PMID: 29631407

Genes

EGFR
BRAF
KRAS
NRAS
PTEN

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Prediction of EGFR blockade responses in metastatic colorectal carcinoma].PMID 29631407Read ↗

[Current Possibilities for Predicting Responses to EGFR Blockade in Metastatic Colorectal Cancer].Semantic proximity Read ↗

[Biomarkers of Anti-EGFR Antibodies in the Treatment of Metastatic Colorectal Cancer].Semantic proximity Read ↗

[Molecular predictive markers of EGFR-targeted therapy in metastatic colorectal cancer].Semantic proximity Read ↗

An empirical review on the resistance mechanisms of epidermal growth factor receptor inhibitors and predictive molecular biomarkers in colorectal cancer.Semantic proximity Read ↗

Molecular Targets for the Treatment of Metastatic Colorectal CancerSemantic proximity Read ↗

The Winding Roadmap of Biomarkers toward Clinic: Lessons from Predictors of Resistance to Anti-EGFRs in Metastatic Colorectal Cancer.Semantic proximity Read ↗

Molecular biomarkers of resistance to anti-EGFR treatment in metastatic colorectal cancer, from classical to innovationSemantic proximity Read ↗

Prognostic and predictive biomarkers in metastatic colorectal cancer anti-EGFR therapy.Semantic proximity Read ↗

EGFR and downstream genetic alterations in KRAS/BRAF and PI3K/AKT pathways in colorectal cancer: implications for targeted therapy.Semantic proximity Read ↗

Treatment of extended RAS/BRAF wild-type metastatic colorectal cancer with anti-EGFR antibody combinations.Semantic proximity Read ↗

[Predictive factors of response to anti-EGFR treatments in colorectal cancer].Semantic proximity Read ↗

Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.